$TMO · THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific reported Q3 2026 results on October 21, 2026. Revenue grew 9% year-over-year to $12.14 billion, with organic revenue growth of 6%. GAAP diluted EPS was $4.64 (up 9%), and adjusted EPS was $6.68 (up 15%). GAAP operating margin expanded to 18.6% from 17.4%, while adjusted operating margin reached 24.5%. The company completed the divestiture of its microbiology business during the quarter. Updated 2026 annual guidance will be provided on the earnings conference call.
- Q3 revenue grew 9% YoY to $12.14 billion, with 6% organic growth.
- GAAP diluted EPS rose 9% to $4.64; adjusted EPS jumped 15% to $6.68.
- GAAP operating margin expanded 120 bps to 18.6%; adjusted operating margin hit 24.5%.
- Laboratory Products and Biopharma Services segment revenue surged to $6.86B from $5.97B.
- Free cash flow reached $2.12 billion, up from $1.84 billion in the prior-year quarter.
Markets closed — no regular-session reaction yet. Extended-hours last trade at $685.14, down 0.32% from the regular close of $687.37, suggesting a muted initial response to the broad-based beat.
A $254B market-cap bellwether delivering 6% organic growth, 15% adjusted EPS growth, and 120 bps of GAAP margin expansion confirms broad-based strength across life sciences end markets.
Thermo Fisher's 6% organic growth and 120 bps GAAP margin expansion reinforce its position as the dominant life sciences tools player, with the Laboratory Products and Biopharma Services segment driving outsized gains.
Restructuring and other costs rose to $199M from $135M YoY, and interest expense increased to $417M from $347M, reflecting higher debt costs. Forward-looking guidance was not provided in the release — it will be disclosed on the earnings call.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.